XTL Biopharmaceutica (Israel) Top Management
XTLB Stock | ILS 5.90 0.10 1.72% |
XTL Biopharmaceutica employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 7 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Analysis of XTL Biopharmaceutica's management performance can provide insight into the company performance.
Itay Weinstein Insider Chief Officer |
Shlomo Shalev Insider CEO Director |
XTL |
XTL Biopharmaceutica Management Team Effectiveness
The company has return on total asset (ROA) of (0.1001) % which means that it has lost $0.1001 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3822 %, meaning that it generated $0.3822 on every $100 dollars invested by stockholders. XTL Biopharmaceutica's management efficiency ratios could be used to measure how well XTL Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.XTL Biopharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. XTL Biopharmaceuticals Price Series Summation is a cross summation of XTL Biopharmaceutica price series and its benchmark/peer.
XTL Biopharmaceutica Notable Stakeholders
A XTL Biopharmaceutica stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as XTL Biopharmaceutica often face trade-offs trying to please all of them. XTL Biopharmaceutica's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting XTL Biopharmaceutica's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Itay Weinstein | Chief Officer | Profile | |
Shlomo Shalev | CEO Director | Profile | |
Ronen Kantor | Company Sec | Profile |
About XTL Biopharmaceutica Management Performance
The success or failure of an entity such as XTL Biopharmaceuticals often depends on how effective the management is. XTL Biopharmaceutica management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of XTL management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the XTL management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. XTL BIOPHARMACEUTI is traded on Tel Aviv Stock Exchange in Israel.
Please note, the presentation of XTL Biopharmaceutica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, XTL Biopharmaceutica's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of XTL Biopharmaceutica's management manipulating its earnings.
XTL Biopharmaceutica Workforce Analysis
Traditionally, organizations such as XTL Biopharmaceutica use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare XTL Biopharmaceutica within its industry.XTL Biopharmaceutica Manpower Efficiency
Return on XTL Biopharmaceutica Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Income Per Employee | 145K | |
Net Income Per Executive | 145K |
Complementary Tools for XTL Stock analysis
When running XTL Biopharmaceutica's price analysis, check to measure XTL Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL Biopharmaceutica is operating at the current time. Most of XTL Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of XTL Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTL Biopharmaceutica's price. Additionally, you may evaluate how the addition of XTL Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |